Austar Lifesciences Limited AULSF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.52% | 18.13% | 10.27% | 8.69% | -5.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.52% | 18.13% | 10.27% | 8.69% | -5.43% |
| Cost of Revenue | 23.25% | 21.81% | 12.66% | 11.04% | -5.76% |
| Gross Profit | 5.50% | 4.27% | 0.39% | -1.05% | -4.17% |
| SG&A Expenses | 9.23% | 7.96% | -11.30% | -12.57% | -0.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -44.95% | -43.26% | 60.29% | 60.87% | 6.89% |
| Total Operating Expenses | 20.05% | 18.66% | 9.47% | 7.90% | -5.71% |
| Operating Income | 2.85% | 1.66% | 52.34% | 50.15% | 4.34% |
| Income Before Tax | -38.07% | -38.79% | 50.89% | 48.74% | 230.35% |
| Income Tax Expenses | 39.87% | 38.23% | 233.61% | 228.82% | 34.06% |
| Earnings from Continuing Operations | -60.14% | -60.60% | 0.21% | -1.22% | 464.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -130.27% | -129.94% | -156.94% | -156.12% | -17.84% |
| Net Income | -64.03% | -64.45% | -12.41% | -13.66% | 325.97% |
| EBIT | 2.85% | 1.66% | 52.34% | 50.15% | 4.34% |
| EBITDA | 6.04% | 4.81% | 22.22% | 20.47% | 4.82% |
| EPS Basic | -64.71% | -64.71% | -14.29% | -14.29% | 325.00% |
| Normalized Basic EPS | -40.00% | -40.00% | 114.29% | 114.29% | 150.00% |
| EPS Diluted | -64.71% | -64.71% | -21.43% | -21.43% | 385.71% |
| Normalized Diluted EPS | -40.00% | -40.00% | 114.29% | 114.29% | 150.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |